Recommended

GSK appoints new CEO
New webinar | Addressing the time-to-result challenge posed by short shelf-life radiopharmaceuticals, register today
Genmab acquires biotech Merus for $8bn
US FDA licensing first for IL-23 inhibitor to treat paediatric psoriasis
Teva makes progress on API business divestment
Takeda to move away from cell therapy
news

Lonza appoints new Chief Executive

2
SHARES

The incoming CEO of the contract development and manufacturing organisation (CDMO) Lonza will transition into his new role over Summer 2024.

Wolfgang Wienand - Lonza CEO (2024)

Wolfgang Wienand (Credit: Lonza)

Wolfgang Wienand has been chosen to succeed Albert Baehny as the CEO of Lonza.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

Wienand will join the contract development and manufacturing organisation (CDMO) in the summer of 2024. He has been CEO of the Swiss CDMO Siegfried Holding AG since 2019.

Baehny has held his Chief Executive Officer ad interim role since October 2023 and will support Wienand through the transition period.

Wienand’s prior roles at Siegfried were as Chief Scientific Officer and then Chief Strategy Officer. Before joining Siegfried in 2010, Wienand worked at the German specialty chemicals company Evonik Industries, Lonza highlighted. 

On his appointment, Wienand, incoming CEO, Lonza shared: “I am very much looking forward to joining Lonza and leading the company into a strong future… [helping to] serve as a partner of choice for the global biopharma industry in its quest to turn breakthrough innovations into viable therapies. Together, we will enable a healthier world for patients in need”.

Wolfgang Wienand – leading the next chapter

 “Wolfgang brings a wealth of knowledge and experience to Lonza, complemented by his deep scientific and strategic expertise. With his proven leadership capabilities, Wolfgang is ideally placed to act as an ambassador for our business and lead our colleague community as Lonza enters the next chapter of its growth journey,” shared Albert Baehny, Chairman of the Board of Directors and CEO ad interim, Lonza.

“I would like to take this chance to thank Albert for his extraordinary dedication and leadership in recent months. As Albert also plans to step down from the Board of Directors in May, I would also like to take this chance to thank him for the critical role he has played in the growth and transformation of our business during his time as Chairman,” Christoph Mäder, Lead Independent Director and Vice-Chairman, Lonza commented.

This announcement follows the company’s news last month in which Lonza agreed to acquire one of the largest biologics manufacturing facilities in the world (by volume) for $1.2 billion.

Share via
Share via